Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Prescription DrugsPain Management

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1457356

Cover Image

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1457356

Opioid Analgesics Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

PUBLISHED:
PAGES: 189 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
PDF (Multi User License)
USD 7600
PDF (Corporate User License)
USD 10600

Add to Cart

Description

Table of Contents

Persistence Market Research presents a comprehensive analysis of the global opioid analgesics market, offering valuable insights into key market dynamics, growth drivers, challenges, and emerging trends This report provides valuable insights into the structure of the Opioid Analgesics Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2023 to 2030.

The global opioid analgesics market is forecast to expand at a CAGR of 5.0% and thereby increase from a value of US$43 Bn in 2023, to US$60.5 Bn by the end of 2030.

Key Insights:

  • Opioid Analgesics Market Size (2023E): US$43 Bn
  • Projected Market Value (2030F): US$60.5 Bn
  • Global Market Growth Rate (CAGR 2023 to 2030): 5.0%
  • Historical Market Growth Rate (CAGR 2018 to 2022): 4.1%

Opioid Analgesics Market - Report Scope:

The opioid analgesics market comprises a wide range of pharmaceutical products utilized for pain management across various medical conditions and procedures. These medications include but are not limited to morphine, oxycodone, hydrocodone, and fentanyl. Market growth is primarily attributed to the increasing prevalence of chronic diseases, surgical interventions, and palliative care requirements worldwide. Additionally, advancements in drug delivery systems and formulations contribute to market expansion.

Market Growth Drivers:

The global opioid analgesics market is fueled by the rising incidence of chronic pain conditions, including cancer pain, neuropathic pain, and musculoskeletal disorders. Moreover, the growing geriatric population, coupled with the increasing number of surgical procedures, amplifies the demand for opioid analgesics for post-operative pain management. Technological advancements in drug delivery systems, such as extended-release formulations and transdermal patches, enhance patient convenience and compliance, further driving market growth.

Market Restraints:

Despite the market's growth potential, certain factors pose challenges to the opioid analgesics market, including concerns regarding opioid abuse, addiction, and regulatory scrutiny. Stringent regulations governing opioid prescribing practices and dispensing regulations aim to mitigate the risk of misuse and diversion. Additionally, the emergence of non-opioid analgesics and alternative pain management therapies presents a competitive challenge to opioid-based medications, impacting market growth to some extent.

Market Opportunities:

The opioid analgesics market presents lucrative opportunities driven by ongoing research and development initiatives aimed at improving the safety and efficacy profiles of opioid medications. Innovations in abuse-deterrent formulations, combination therapies, and personalized medicine approaches hold promise for addressing unmet medical needs and expanding the market reach. Furthermore, the growing focus on palliative care and hospice services underscores the demand for effective pain management solutions, creating avenues for market growth and differentiation.

Key Questions Answered in the Report:

  • Which regions are poised to lead the growth of the opioid analgesics market?
  • What factors influence the adoption of opioid analgesics across different medical conditions and patient demographics?
  • How are regulatory trends and technological advancements shaping the competitive landscape of the opioid analgesics market?
  • Who are the key players driving innovation and market expansion in the opioid analgesics segment?
  • What are the emerging trends and prospects in the global opioid analgesics market?

Competitive Intelligence and Business Strategy:

Leading players in the global opioid analgesics market, including Pfizer Inc., Abbott Laboratories, Janssen Pharmaceuticals, Inc. [Johnson & Johnson], Novartis AG, Bayer AG, GlaxoSmithKline plc, prioritize innovation and strategic collaborations to maintain market leadership. These companies invest significantly in research and development to introduce novel opioid formulations, adhere to regulatory compliance, and address public health concerns associated with opioid use. Moreover, strategic partnerships with healthcare providers, pain management specialists, and advocacy groups facilitate market penetration and enhance patient access to opioid analgesics.

Key Companies Profiled:

  • Pfizer Inc.
  • Abbott Laboratories
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG,
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals
  • AbbVie Inc. (Allergan plc)
  • Purdue Pharmaceuticals L.P.
  • Sun Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]

Opioid Analgesics Market Research Segmentation:

By Drug Class:

  • Morphine
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Tramadol
  • Oxycodone
  • Dextromethorphan
  • Buprenorphine
  • Others

By Indication:

  • Surgical Pain
  • Cancer Pain
  • Neuropathic Pain
  • Other

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal
  • Other

By End-User:

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa
Show more
Product Code: PMRREP33953

Table of Contents

1. Executive Summary

  • 1.1. Global Opioid Analgesics Market Snapshot, 2023 and 2030
  • 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Drug Class Lifecycle Analysis
  • 2.4. Opioid Analgesics Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Applications
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Mn) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2013-2016
    • 3.2.2. Current Market Size Forecast, 2018-2026
  • 3.3. Global Opioid Analgesics Market Outlook: Drug Class
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Class, 2018 - 2022
    • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
      • 3.3.3.1. Morphine
      • 3.3.3.2. Codeine
      • 3.3.3.3. Fentanyl
      • 3.3.3.4. Meperidine
      • 3.3.3.5. Methadone
      • 3.3.3.6. Tramadol
      • 3.3.3.7. Oxycodone
      • 3.3.3.8. Dextromethorphan
      • 3.3.3.9. Buprenorphine
      • 3.3.3.10. Others
  • 3.4. Market Attractiveness Analysis: Drug Class
  • 3.5. Global Opioid Analgesics Market Outlook: Indication
    • 3.5.1. Introduction / Key Findings
    • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Indication, 2018 - 2022
    • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
      • 3.5.3.1. Surgical Pain
      • 3.5.3.2. Cancer Pain
      • 3.5.3.3. Neuropathic Pain
      • 3.5.3.4. Other
  • 3.6. Market Attractiveness Analysis: Indication
  • 3.7. Global Opioid Analgesics Market Outlook: Route of Administration
    • 3.7.1. Introduction / Key Findings
    • 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Route of Administration, 2018 - 2022
    • 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
      • 3.7.3.1. Oral
      • 3.7.3.2. Parenteral
      • 3.7.3.3. Transdermal
      • 3.7.3.4. Other
  • 3.8. Market Attractiveness Analysis: Route of Administration
  • 3.9. Global Opioid Analgesics Market Outlook: End User
    • 3.9.1. Introduction / Key Findings
    • 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End User, 2018 - 2022
    • 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
      • 3.9.3.1. Hospitals
      • 3.9.3.2. Retail Pharmacies
      • 3.9.3.3. Drug Stores
      • 3.9.3.4. Online Pharmacies
  • 3.10. Market Attractiveness Analysis: End User

4. Global Opioid Analgesics Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
  • 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia and Oceania
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 5.3.1. By Country
    • 5.3.2. By Drug Class
    • 5.3.3. By Indication
    • 5.3.4. By Route of Administration
    • 5.3.5. By End User
  • 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
    • 5.5.1. Morphine
    • 5.5.2. Codeine
    • 5.5.3. Fentanyl
    • 5.5.4. Meperidine
    • 5.5.5. Methadone
    • 5.5.6. Tramadol
    • 5.5.7. Oxycodone
    • 5.5.8. Dextromethorphan
    • 5.5.9. Buprenorphine
    • 5.5.10. Others
  • 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
    • 5.6.1. Surgical Pain
    • 5.6.2. Cancer Pain
    • 5.6.3. Neuropathic Pain
    • 5.6.4. Other
  • 5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 5.7.1. Oral
    • 5.7.2. Parenteral
    • 5.7.3. Transdermal
    • 5.7.4. Other
  • 5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 5.8.1. Hospitals
    • 5.8.2. Retail Pharmacies
    • 5.8.3. Drug Stores
    • 5.8.4. Online Pharmacies
  • 5.9. Market Attractiveness Analysis

6. Europe Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 6.3.1. By Country
    • 6.3.2. By Drug Class
    • 6.3.3. By Indication
    • 6.3.4. By Route of Administration
    • 6.3.5. By End User
  • 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. Turkiye
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
    • 6.5.1. Morphine
    • 6.5.2. Codeine
    • 6.5.3. Fentanyl
    • 6.5.4. Meperidine
    • 6.5.5. Methadone
    • 6.5.6. Tramadol
    • 6.5.7. Oxycodone
    • 6.5.8. Dextromethorphan
    • 6.5.9. Buprenorphine
    • 6.5.10. Others
  • 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
    • 6.6.1. Surgical Pain
    • 6.6.2. Cancer Pain
    • 6.6.3. Neuropathic Pain
    • 6.6.4. Other
  • 6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 6.7.1. Oral
    • 6.7.2. Parenteral
    • 6.7.3. Transdermal
    • 6.7.4. Other
  • 6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 6.8.1. Hospitals
    • 6.8.2. Retail Pharmacies
    • 6.8.3. Drug Stores
    • 6.8.4. Online Pharmacies
  • 6.9. Market Attractiveness Analysis

7. East Asia Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 7.3.1. By Country
    • 7.3.2. By Drug Class
    • 7.3.3. By Indication
    • 7.3.4. By Route of Administration
    • 7.3.5. By End User
  • 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
    • 7.5.1. Morphine
    • 7.5.2. Codeine
    • 7.5.3. Fentanyl
    • 7.5.4. Meperidine
    • 7.5.5. Methadone
    • 7.5.6. Tramadol
    • 7.5.7. Oxycodone
    • 7.5.8. Dextromethorphan
    • 7.5.9. Buprenorphine
    • 7.5.10. Others
  • 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
    • 7.6.1. Surgical Pain
    • 7.6.2. Cancer Pain
    • 7.6.3. Neuropathic Pain
    • 7.6.4. Other
  • 7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 7.7.1. Oral
    • 7.7.2. Parenteral
    • 7.7.3. Transdermal
    • 7.7.4. Other
  • 7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 7.8.1. Hospitals
    • 7.8.2. Retail Pharmacies
    • 7.8.3. Drug Stores
    • 7.8.4. Online Pharmacies
  • 7.9. Market Attractiveness Analysis

8. South Asia & Oceania Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 8.3.1. By Country
    • 8.3.2. By Drug Class
    • 8.3.3. By Indication
    • 8.3.4. By Route of Administration
    • 8.3.5. By End User
  • 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Oceania
  • 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
    • 8.5.1. Morphine
    • 8.5.2. Codeine
    • 8.5.3. Fentanyl
    • 8.5.4. Meperidine
    • 8.5.5. Methadone
    • 8.5.6. Tramadol
    • 8.5.7. Oxycodone
    • 8.5.8. Dextromethorphan
    • 8.5.9. Buprenorphine
    • 8.5.10. Others
  • 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
    • 8.6.1. Surgical Pain
    • 8.6.2. Cancer Pain
    • 8.6.3. Neuropathic Pain
    • 8.6.4. Other
  • 8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 8.7.1. Oral
    • 8.7.2. Parenteral
    • 8.7.3. Transdermal
    • 8.7.4. Other
  • 8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 8.8.1. Hospitals
    • 8.8.2. Retail Pharmacies
    • 8.8.3. Drug Stores
    • 8.8.4. Online Pharmacies
  • 8.9. Market Attractiveness Analysis

9. Latin America Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 9.3.1. By Country
    • 9.3.2. By Drug Class
    • 9.3.3. By Indication
    • 9.3.4. By Route of Administration
    • 9.3.5. By End User
  • 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
    • 9.5.1. Morphine
    • 9.5.2. Codeine
    • 9.5.3. Fentanyl
    • 9.5.4. Meperidine
    • 9.5.5. Methadone
    • 9.5.6. Tramadol
    • 9.5.7. Oxycodone
    • 9.5.8. Dextromethorphan
    • 9.5.9. Buprenorphine
    • 9.5.10. Others
  • 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
    • 9.6.1. Surgical Pain
    • 9.6.2. Cancer Pain
    • 9.6.3. Neuropathic Pain
    • 9.6.4. Other
  • 9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 9.7.1. Oral
    • 9.7.2. Parenteral
    • 9.7.3. Transdermal
    • 9.7.4. Other
  • 9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 9.8.1. Hospitals
    • 9.8.2. Retail Pharmacies
    • 9.8.3. Drug Stores
    • 9.8.4. Online Pharmacies
  • 9.9. Market Attractiveness Analysis

10. Middle East & Africa Opioid Analgesics Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
    • 10.3.1. By Country
    • 10.3.2. By Drug Class
    • 10.3.3. By Indication
    • 10.3.4. By Route of Administration
    • 10.3.5. By End User
  • 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Class, 2023 - 2030
    • 10.5.1. \Morphine
    • 10.5.2. Codeine
    • 10.5.3. Fentanyl
    • 10.5.4. Meperidine
    • 10.5.5. Methadone
    • 10.5.6. Tramadol
    • 10.5.7. Oxycodone
    • 10.5.8. Dextromethorphan
    • 10.5.9. Buprenorphine
    • 10.5.10. Others
  • 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication, 2023 - 2030
    • 10.6.1. Surgical Pain
    • 10.6.2. Cancer Pain
    • 10.6.3. Neuropathic Pain
    • 10.6.4. Other
  • 10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
    • 10.7.1. Oral
    • 10.7.2. Parenteral
    • 10.7.3. Transdermal
    • 10.7.4. Other
  • 10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 10.8.1. Hospitals
    • 10.8.2. Retail Pharmacies
    • 10.8.3. Drug Stores
    • 10.8.4. Online Pharmacies
  • 10.9. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2022
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition Dashboard
    • 11.2.3. Apparent Product Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Product
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Abbott Laboratories
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Product
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Product
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. Novartis AG
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Product
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. Bayer AG
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Product
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. GlaxoSmithKline plc
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Product
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy
    • 11.3.7. F. Hoffmann-La Roche AG
      • 11.3.7.1. Overview
      • 11.3.7.2. Segments and Product
      • 11.3.7.3. Key Financials
      • 11.3.7.4. Market Developments
      • 11.3.7.5. Market Strategy
    • 11.3.8. Boehringer Ingelheim International GmbH
      • 11.3.8.1. Overview
      • 11.3.8.2. Segments and Product
      • 11.3.8.3. Key Financials
      • 11.3.8.4. Market Developments
      • 11.3.8.5. Market Strategy
    • 11.3.9. Bausch Health Companies Inc.
      • 11.3.9.1. Overview
      • 11.3.9.2. Segments and Product
      • 11.3.9.3. Key Financials
      • 11.3.9.4. Market Developments
      • 11.3.9.5. Market Strategy
    • 11.3.10. Sanofi S.A.
      • 11.3.10.1. Overview
      • 11.3.10.2. Segments and Product
      • 11.3.10.3. Key Financials
      • 11.3.10.4. Market Developments
      • 11.3.10.5. Market Strategy
    • 11.3.11. Teva Pharmaceuticals
      • 11.3.11.1. Overview
      • 11.3.11.2. Segments and Product
      • 11.3.11.3. Key Financials
      • 11.3.11.4. Market Developments
      • 11.3.11.5. Market Strategy
    • 11.3.12. AbbVie Inc. (Allergan plc)
      • 11.3.12.1. Overview
      • 11.3.12.2. Segments and Product
      • 11.3.12.3. Key Financials
      • 11.3.12.4. Market Developments
      • 11.3.12.5. Market Strategy
    • 11.3.13. Purdue Pharmaceuticals L.P.
      • 11.3.13.1. Overview
      • 11.3.13.2. Segments and Product
      • 11.3.13.3. Key Financials
      • 11.3.13.4. Market Developments
      • 11.3.13.5. Market Strategy
    • 11.3.14. Sun Pharmaceutical Industries Ltd.
      • 11.3.14.1. Overview
      • 11.3.14.2. Segments and Product
      • 11.3.14.3. Key Financials
      • 11.3.14.4. Market Developments
      • 11.3.14.5. Market Strategy
    • 11.3.15. Mallinckrodt Pharmaceuticals
      • 11.3.15.1. Overview
      • 11.3.15.2. Segments and Product
      • 11.3.15.3. Key Financials
      • 11.3.15.4. Market Developments
      • 11.3.15.5. Market Strategy
    • 11.3.16. Endo Pharmaceuticals Inc. [Endo International plc]
      • 11.3.16.1. Overview
      • 11.3.16.2. Segments and Product
      • 11.3.16.3. Key Financials
      • 11.3.16.4. Market Developments
      • 11.3.16.5. Market Strategy
    • 11.3.17. Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]
      • 11.3.17.1. Overview
      • 11.3.17.2. Segments and Product
      • 11.3.17.3. Key Financials
      • 11.3.17.4. Market Developments
      • 11.3.17.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!